Double radiation attack tested on hard-to-treat gut tumors

NCT ID NCT07150546

Recruiting now Disease control Sponsor: Emory University Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 27 times

Summary

This early-phase trial tests whether adding a precise external radiation treatment (SBRT) before a standard radioactive drug therapy (177Lu-DOTATATE) is safe and works better for people with large, inoperable digestive neuroendocrine tumors. About 15 adults whose tumors have grown despite prior treatments will receive both therapies. The main goal is to check for serious side effects, with a secondary focus on tumor shrinkage.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UNRESECTABLE DIGESTIVE SYSTEM NEUROENDOCRINE TUMOR G1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Emory University Hospital
RECRUITING

Atlanta, Georgia, 30322, United States

Contact Email: •••••@•••••

Contact
Emory University Hospital Midtown
RECRUITING

Atlanta, Georgia, 30308, United States

Contact Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

DIGESTIVE SYSTEM NEUROENDOCRINE TUMOR UNRESECTABLE DIGESTIVE SYSTEM NEUROENDOCRINE NEOPLASM UNRESECTABLE DIGESTIVE SYSTEM NEUROENDOCRINE TUMOR G1 UNRESECTABLE DIGESTIVE SYSTEM NEUROENDOCRINE TUMOR G2